| 【Company Research】CSPC Pharmaceutical (1093 HK) – mRNA platform verified with product approval |
| 【Company Research】Jiumaojiu (9922 HK) – Post pandemic margin recovery is the key |
| 【Company Research】Tencent (700 HK) – Steady ship and aim for sustainable growth |
| 【Company Research】Xtep (1368 HK) – Excellent YTD performance among all brands |
| 【Company Research】Huya Inc. (HUYA US) – Moving into mild recovery in 2H23E |
| 【Company Research】Hongjiu Fruits (6689 HK) – A solid and robust 2022; all eyes on the upcoming OCF turnaround |
| 【Company Research】WuXi AppTec (603259 CH) – Non-COVID business to maintain solid growth |
| 【Company Research】Kindly Medical (1501 HK) – Rich portfolios guarantee recovery in 2023E |
| 【Company Research】TME (TME US) – Expect a year of mild recovery in FY23 |
| 【Company Research】ZhongAn (6060 HK) – Better profits achieved across 3 business lines |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
